BeiGene (SHSE:688235) Total Liabilities : ¥16,978 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is BeiGene Total Liabilities?

BeiGene's Total Liabilities for the quarter that ended in Mar. 2025 was ¥16,978 Mil.

BeiGene's quarterly Total Liabilities increased from Sep. 2024 (¥16,945.51 Mil) to Dec. 2024 (¥18,847.46 Mil) but then declined from Dec. 2024 (¥18,847.46 Mil) to Mar. 2025 (¥16,977.96 Mil).

BeiGene's annual Total Liabilities increased from Dec. 2022 (¥13,915.06 Mil) to Dec. 2023 (¥16,193.60 Mil) and increased from Dec. 2023 (¥16,193.60 Mil) to Dec. 2024 (¥18,847.46 Mil).

BeiGene Total Liabilities Historical Data

The historical data trend for BeiGene's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Liabilities Chart

BeiGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

11,322.89

15,305.19

13,915.06

16,193.60

18,847.46

BeiGene Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															16,616.17	17,018.98	16,945.51	18,847.46	16,977.96

BeiGene Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BeiGene's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16126.015	+	(1534.488	+	540.898
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	526.62	+	119.44	+	0)
	=	18,847

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	43108.369	-	24260.909
	=	18,847

BeiGene's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14380.589	+	(1558.976	+	391.252
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	528.786	+	118.352	+	0)
	=	16,978

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	42346.974	-	25369.02
	=	16,978

BeiGene Total Liabilities Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 06160:Hong Kong 49B:Germany 49B:Germany 49BA:Germany 49BA:Germany B1ME34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines